Trial reportMedical science monitor : international medical journal of experimental and clinical research2018
Changes of Serum Procalcitonin (PCT), C-Reactive Protein (CRP), Interleukin-17 (IL-17), Interleukin-6 (IL-6), High Mobility Group Protein-B1 (HMGB1) and D-Dimer in Patients with Severe Acute Pancreatitis Treated with Continuous Renal Replacement Therapy (CRRT) and Its Clinical Significance.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- High mobility group box 1 and its post-translational modifications: Molecular mechanisms underlying neurodegenerative disease pathogenesis.Neural regeneration research · 2026Article
- Procalcitonin kinetics in critically ill patients: a retrospective analysis of the impact of renal dysfunction and renal replacement therapy.Journal of anesthesia, analgesia and critical care · 2026Article
- Procalcitonin kinetics in critically ill children: impact of continuous kidney replacement therapy modality and dose.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Article
- Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: protocol for a randomized controlled trial.Frontiers in medicine · 2026Article
- Predictive Value of SerumDiagnostics (Basel, Switzerland) · 2025Article
- Traditional Chinese medicine formulas alleviated acute pancreatitis via improvement of microcirculation: A systematic review and meta-analysis.Chinese herbal medicines · 2025Article
- Use of procalcitonin in therapeutic decisions in the pediatric intensive care unit.Annals of intensive care · 2025Review
- Procalcitonin as a Predictor of Mortality in Patients With Severe Acute Pancreatitis.Gastroenterology research · 2025Article
- Early enteral nutrition with fructooligosaccharides improves prognosis in severe acute pancreatitis.Scientific reports · 2025Article
- Oxidative stress, DAMPs, and immune cells in acute pancreatitis: molecular mechanisms and therapeutic prospects.Frontiers in immunology · 2025Review
- Utilizing MRI Radiomics and Clinical Features to Predict Severe Acute Pancreatitis in Patients with Metabolic Syndrome.Journal of inflammation research · 2025Article
- An inflammation-based model for identifying severe acute pancreatitis: a single-center retrospective study.BMC gastroenterology · 2024Article
- Computerized tomography-guided therapeutic percutaneous puncture catheter drainage-combined with somatostatin for severe acute pancreatitis: An analysis of efficacy and safety.World journal of gastrointestinal surgery · 2024Article
- Evaluation of the therapeutic efficiency and efficacy of blood purification in the treatment of severe acute pancreatitis.PloS one · 2024Article
- Evaluating the Therapeutic Efficiency and Efficacy of Blood Purification for Treating Severe Acute Pancreatitis: A Single-Center Data Based on Propensity Score Matching.International journal of general medicine · 2024Article
- Evaluating the efficacy and timing of blood purification modalities in early-stage hyperlipidemic acute pancreatitis treatment.Lipids in health and disease · 2023Review
- Effects of metformin therapy on HMGB1 levels in rheumatoid arthritis patients.European journal of medical research · 2023Article
- The clinical characteristics of focal acute pancreatitis based on imaging diagnosis: comparison with non-localized acute pancreatitis- a preliminary result.BMC gastroenterology · 2023Review
- Hemorheological and Microcirculatory Relations of Acute Pancreatitis.Metabolites · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to investigate the changes in serum levels of procalcitonin (PCT), C-reactive protein (CRP), interleukin-17 (IL-17), interleukin-6 (IL-6), high mobility group protein-B1 (HMGB1), and D-dimer in severe acute pancreatitis (SAP) patients during treatment with continuous renal replacement therapy (CRRT) and the clinical significance. MATERIAL AND METHODS A total of 92 SAP patients admitted to our hospital from January 2017 to December 2017 were selected and randomly divided into the observation group and the control group using a random number table method, with 46 cases in each group. The control group was given conventional therapy, and the observation group was given CRRT in addition to conventional therapy. RESULTS After 1 week, the total effective rate of treatment in the observation group was significantly higher than that in the control group (P<0.05). In the observation group, each index showed a continuous downward trend at 6, 12, and 24 hours after treatment, and at different time points after treatment, the indexes were significantly lower than those in the control group (P<0.05). CONCLUSIONS CRRT is more effective in the treatment of SAP, and its effects are more obvious in removing a variety of inflammatory factors and reducing the serum levels of PCT, HMGB1, and D-dimer, which is of great clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.